Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Roche : Invitation to Roche's live audio webcast on efficacy and safety of risdiplam in patients with type 2/3 spinal muscular atrophy presented at SMA Europe 2020

share with twitter share with LinkedIn share with facebook
share via e-mail
01/17/2020 | 04:14am EST

We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Thursday, 6 February 2020, highlighting Roche data on risdiplam in type 2/3 spinal muscular atrophy from the SUNFISH Part 2 trial presented at the 2nd International Scientific Congress on Spinal Muscular Atrophy, (5 - 7 Feb) in Evry, France.

Please dial in as outlined below:
15:00 - 15:45 CET / 14:00 - 14:45 GMT
09:00 - 09:45 am EST / 06:00 - 06:45 am PST

Audio webcast and conference call will start with presentations followed by a Q&A session (live access to the speakers).

Access to Audio webcast
Please access by clicking on > ir.roche.com

Access to Conference Call (pre-registration required)
You will receive phone numbers, passcode and your personal PIN to direct access the conference call by pre-registering here.

Should you have any issues with the registration, please dial the following numbers on the day of the conference call 10-15 minutes prior to conference start:

+41 (0) 58 310 50 00 (Europe & RoW)
+44 (0) 207 107 0613 (UK)
+1 631 570 56 13 (USA)

A replay of the webcast will be available via > ir.roche.com

Disclaimer

Roche Holding AG published this content on 17 January 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 January 2020 09:13:00 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING AG
02/14CHUGAI PHARMACEUTICAL : Foundation Medicine and Chugai Announce Partnership with..
AQ
02/14CHUGAI PHARMACEUTICAL : Polatuzumab Vedotin Achieved Primary Endpoint in the Jap..
AQ
02/14Sosei Heptares Operational Highlights and Consolidated Results for the 12 Mon..
AQ
02/14China National Medical Products Administration grants approval of Roche's Tec..
GL
02/13CHUGAI PHARMACEUTICAL : Wins Second Prize for the Second Consecutive Year in the..
AQ
02/13CHUGAI PHARMACEUTICAL : Joins the Consortium of Companies Promoting Anti-Smoking..
AQ
02/11ELI LILLY AND : Lilly Announces Topline Results for Solanezumab from the Dominan..
AQ
02/11ROCHE : Genentech Provides Topline Results From Investigator-Led Phase II/III Tr..
AQ
02/11REMINDER : Invitation to Roche's Virtual Early Drug Development gRED Event 2020
PU
02/10Lilly, Roche Drugs Fail to Halt Inherited Form of Alzheimer's -- 2nd Update
DJ
More news
Financials (CHF)
Sales 2020 62 679 M
EBIT 2020 23 166 M
Net income 2020 15 364 M
Finance 2020 3 374 M
Yield 2020 2,72%
P/E ratio 2020 19,8x
P/E ratio 2021 18,6x
EV / Sales2020 4,56x
EV / Sales2021 4,33x
Capitalization 289 B
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 342,14  CHF
Last Close Price 340,60  CHF
Spread / Highest target 11,9%
Spread / Average Target 0,45%
Spread / Lowest Target -31,3%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG9.79%294 912
JOHNSON & JOHNSON2.92%395 123
NOVARTIS4.27%220 633
MERCK AND COMPANY-9.13%210 426
PFIZER-5.74%202 051
BRISTOL-MYERS SQUIBB COMPANY2.94%149 421